LONDON: RTW Biotech Opportunities Ltd, the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, notes the announcement by one of its private portfolio companies, Aktis Oncology, Inc. (“Aktis”) regarding the pricing of its $318 million initial public offering (“IPO”).
Aktis’ IPO raised $318 million by offering 17.65 million shares at $18 per share. This valuation represents a 12.6% step-up from RTW Bio’s prior holding value at 30 November 2025 and a 18.3% step-up from the cost at the time of purchase in September 2024. Aktis began trading on the Nasdaq Global Select Market under the ticker “AKTS” on 9 January 2026, where the stock traded up 24.4% to close at $22.40 per share. As of 30 November 2025, Aktis represented 0.6% of the RTW Bio’s NAV.
Aktis is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations. Its lead programme targets Nectin-4, a miniprotein radioconjugate with multi-indication potential across multiple tumour types.
Rod Wong, CIO of RTW Investments, said, “We are thrilled to have supported the first biotech IPO of the year, which marks a significant milestone for Aktis and for the field of targeted radiopharmaceuticals. Aktis’ rapid progress reflects the transformative potential we seek in our portfolio companies and underscores our commitment to identifying and supporting assets that drive meaningful advances in patient care.”